CA2247814A1 - Pharmaceutically useful compounds - Google Patents

Pharmaceutically useful compounds Download PDF

Info

Publication number
CA2247814A1
CA2247814A1 CA002247814A CA2247814A CA2247814A1 CA 2247814 A1 CA2247814 A1 CA 2247814A1 CA 002247814 A CA002247814 A CA 002247814A CA 2247814 A CA2247814 A CA 2247814A CA 2247814 A1 CA2247814 A1 CA 2247814A1
Authority
CA
Canada
Prior art keywords
pyrazolo
hydroxy
bond
methyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002247814A
Other languages
English (en)
French (fr)
Inventor
Mark Furber
John Bantick
Simon Hirst
Roger Bonnert
Matthew Perry
David Donald
Eifion Phillips
Peter Cage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605803.7A external-priority patent/GB9605803D0/en
Priority claimed from GBGB9610474.0A external-priority patent/GB9610474D0/en
Priority claimed from GBGB9610894.9A external-priority patent/GB9610894D0/en
Priority claimed from GBGB9700862.7A external-priority patent/GB9700862D0/en
Application filed by Individual filed Critical Individual
Publication of CA2247814A1 publication Critical patent/CA2247814A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002247814A 1996-03-20 1997-03-20 Pharmaceutically useful compounds Abandoned CA2247814A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9605803.7A GB9605803D0 (en) 1996-03-20 1996-03-20 Pharmaceutically-active compound
GB9605803.7 1996-03-20
GB9610474.0 1996-05-18
GBGB9610474.0A GB9610474D0 (en) 1996-05-18 1996-05-18 Pharmaceutically active compounds
GB9610894.9 1996-05-24
GBGB9610894.9A GB9610894D0 (en) 1996-05-24 1996-05-24 Pharmaceutically useful compounds
GBGB9700862.7A GB9700862D0 (en) 1997-01-16 1997-01-16 Pharmaceutically useful compounds
GB9700862.7 1997-01-16

Publications (1)

Publication Number Publication Date
CA2247814A1 true CA2247814A1 (en) 1997-09-25

Family

ID=27451427

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002247814A Abandoned CA2247814A1 (en) 1996-03-20 1997-03-20 Pharmaceutically useful compounds

Country Status (19)

Country Link
EP (1) EP0888347A1 (xx)
JP (1) JP2000506884A (xx)
KR (1) KR20000064716A (xx)
CN (1) CN1218472A (xx)
AR (1) AR006520A1 (xx)
AU (1) AU712141B2 (xx)
BR (1) BR9708103A (xx)
CA (1) CA2247814A1 (xx)
CZ (1) CZ297798A3 (xx)
EE (1) EE9800298A (xx)
ID (1) ID16283A (xx)
IL (1) IL126271A0 (xx)
IS (1) IS4848A (xx)
NO (1) NO984290L (xx)
NZ (1) NZ331614A (xx)
PL (1) PL328921A1 (xx)
SK (1) SK118798A3 (xx)
TR (1) TR199801861T2 (xx)
WO (1) WO1997034893A1 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10110749A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
JP2003002863A (ja) * 2001-06-25 2003-01-08 Nippon Soda Co Ltd 安息香酸類の製造方法および新規化合物
SE0102404D0 (sv) * 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds
US6642249B2 (en) 2001-07-04 2003-11-04 Active Biotech Ab Immunomodulating compounds
DE10229762A1 (de) * 2002-07-03 2004-01-22 Aventis Pharma Deutschland Gmbh Pyrazoloisoquinolinenderivaten zur Inhibierung von NFkappaB-induzierende Kinase
EP1813616B1 (en) * 2002-11-22 2013-03-27 Active Biotech AB Pyrazoloquinolines with immunomodulating activity
DE60326639D1 (de) * 2002-12-16 2009-04-23 Active Biotech Ab Tetrazyklische immunmodulierende verbindungen
US7276505B2 (en) 2003-03-14 2007-10-02 Medigene Limited Immunomodulating heterocyclic compounds
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
BRPI0417543A (pt) 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
FR2870239B1 (fr) * 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
WO2006016093A1 (en) * 2004-08-09 2006-02-16 Avidex Limited Immunomodulating oxopyrrazolocinnolines as cd80 inhibitors
CN101541757A (zh) 2006-10-31 2009-09-23 辉瑞产品公司 作为盐皮质激素受体拮抗剂的吡唑啉类化合物
CN102372710A (zh) * 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 作为盐皮质激素受体拮抗剂的并环类化合物
JPWO2012108511A1 (ja) 2011-02-09 2014-07-03 日産化学工業株式会社 ピラゾール誘導体および有害生物防除剤
EP3846904B1 (en) * 2018-09-07 2023-05-31 Merck Patent GmbH 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
JP2023533724A (ja) 2020-07-02 2023-08-04 インサイト・コーポレイション Jak2 v617f阻害剤としての三環式尿素化合物
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
WO2023178285A1 (en) 2022-03-17 2023-09-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524146A (en) * 1982-12-08 1985-06-18 Ciba-Geigy Corporation Certain -2-heterocycle substituted pyrazoloquinolines
JPS61112075A (ja) * 1984-11-05 1986-05-30 Shionogi & Co Ltd チエニルピラゾロキノリン誘導体
SE8903564D0 (sv) * 1989-10-26 1989-10-26 Pharmacia Ab New use condensed quinoline compound
JPH05194515A (ja) * 1991-07-31 1993-08-03 Kyowa Hakko Kogyo Co Ltd 縮合ナフチリジン誘導体

Also Published As

Publication number Publication date
IS4848A (is) 1998-09-16
NZ331614A (en) 2000-07-28
BR9708103A (pt) 1999-07-27
AU2186797A (en) 1997-10-10
IL126271A0 (en) 1999-05-09
JP2000506884A (ja) 2000-06-06
AU712141B2 (en) 1999-10-28
EE9800298A (et) 1999-02-15
NO984290D0 (no) 1998-09-16
AR006520A1 (es) 1999-09-08
EP0888347A1 (en) 1999-01-07
SK118798A3 (en) 1999-03-12
ID16283A (id) 1997-09-18
WO1997034893A1 (en) 1997-09-25
CZ297798A3 (cs) 1999-03-17
CN1218472A (zh) 1999-06-02
NO984290L (no) 1998-10-27
TR199801861T2 (xx) 1998-12-21
PL328921A1 (en) 1999-03-01
KR20000064716A (ko) 2000-11-06

Similar Documents

Publication Publication Date Title
CA2247814A1 (en) Pharmaceutically useful compounds
CA2166721C (en) Bicyclic tetrahydro pyrazolopyridines
JP2862375B2 (ja) Crfアンタゴニストとしてのピラゾロピリミジン
US5134142A (en) Pyrazole derivatives, and pharmaceutical composition comprising the same
US4810719A (en) Anti-inflammator 1,n-diarylpyrazol-3-amines
ES2280599T3 (es) Derivados de 5,6-diaril-pirazin-2-amida como antagonistas de cb1.
JP2003511452A (ja) ホスホジエステラーゼ阻害剤としての5−(2−置換−5−ヘテロシクリルスルホニルピリド−3−イル)−ジヒドロピラゾロ[4,3−d]ピリミジン−7−オン
JP2008525404A (ja) 治療剤
JPH0256484A (ja) 縮合ピリミジン誘導体およびその製造方法
JPH07509725A (ja) Crfアンタゴニスト活性を有するピラゾール及びピラゾロピリミジン
WO1995028387A1 (fr) Compose benzamide et utilisation medicale dudit compose
JP2000128883A (ja) 性的機能障害の治療用のピラゾロピリミジノンcGMPPDE5阻害剤
JP2002508780A (ja) 新規な化合物
KR20000069605A (ko) 피롤로[3,4-d]피리미디논 유도체 및 약제로서의 이의 용도
JP2007531723A (ja) 治療薬
EP0077983B1 (en) Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
WO2003033478A1 (en) Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
AU639043B2 (en) Pyridazine derivatives, process for their preparation and pharmaceutical compositions containing them
JPH0517470A (ja) ピラゾール誘導体
EP0201765A2 (en) 3(2H)Pyridazinone, process for its preparation and anti-allergic agent containing it
JPH0768228B2 (ja) アリールトリアジン構造を有する新規化合物、その製造方法並びにこれを含む医薬組成物
RU2116308C1 (ru) Триазолпиримидиновые производные и фармацевтическая композиция
JPH0528701B2 (xx)
US7148222B2 (en) Substituted pyrido-pyridazine derivatives which enhance cognition via the GABA-A receptors
JP2001509509A (ja) 新規な化合物

Legal Events

Date Code Title Description
FZDE Discontinued